SARS-CoV-2-IN-22

HY-146157	
2710278-53-6	N
C ₂₇ H ₂₄ N ₂ O ₃ S	
456.56	∫ S_
SARS-CoV) OH
Anti-infection	
Please store the product under the recommended conditions in the Certificate of Analysis.	СН
	2710278-53-6 C ₂₇ H ₂₄ N ₂ O ₃ S 456.56 SARS-CoV Anti-infection Please store the product under the recommended conditions in the Certificate of

BIOLOGICAL ACTIVITY	
Description	SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus entry inhibitor with an IC $_{50}$ value of 16.96 $\mu M^{[1]}.$
IC ₅₀ & Target	IC50: 16.96 μM (SARS-CoV-2) ^[1]
In Vitro	SARS-CoV-2-IN-22 (Compound 9a) effectively blocks the binding of SARS-CoV-2 to the host ACE2 receptor through dual recognition of SARS-CoV-2 spike receptor-binding domain (RBD) and human ACE2. SARS-CoV-2-IN-2 displays no cytotoxicity to normal cells (LO2) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Ting Xu, et al. Discovery of honokiol thioethers containing 1,3,4-oxadiazole moieties as potential α-glucosidase and SARS-CoV-2 entry inhibitors. Bioorg Med Chem. 2022 Aug 1;67:116838.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Product Data Sheet